Daniel J Sargent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3680970/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Comparison of Laparoscopically Assisted and Open Colectomy for Colon Cancer. New England Journal of Medicine, 2004, 350, 2050-2059.	27.0	3,258
2	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 303-312.	13.7	2,276
3	A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 23-30.	1.6	2,112
4	Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. New England Journal of Medicine, 2003, 349, 247-257.	27.0	1,962
5	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	13.7	1,487
6	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. Journal of Clinical Oncology, 2010, 28, 3219-3226.	1.6	1,352
7	Guidelines 2000 for Colon and Rectal Cancer Surgery. Journal of the National Cancer Institute, 2001, 93, 583-596.	6.3	1,174
8	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. Journal of Clinical Oncology, 2009, 27, 3677-3683.	1.6	1,166
9	Prognostic Factors in Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2000, 124, 979-994.	2.5	1,027
10	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 2004, 22, 1209-1214.	1.6	1,007
11	Laparoscopic Colectomy for Cancer Is Not Inferior to Open Surgery Based on 5-Year Data From the COST Study Group Trial. Annals of Surgery, 2007, 246, 655-664.	4.2	962
12	A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. New England Journal of Medicine, 2001, 345, 1091-1097.	27.0	931
13	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. Journal of Clinical Oncology, 2004, 22, 1797-1806.	1.6	913
14	Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes. JAMA - Journal of the American Medical Association, 2015, 314, 1346.	7.4	898
15	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1729.	7.4	711
16	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. New England Journal of Medicine, 2018, 378, 1177-1188.	27.0	699
17	Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2002, 287, 321.	7.4	675
18	Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). Journal of Clinical Oncology, 2008, 26, 5326-5334.	1.6	654

#	Article	IF	CITATIONS
19	Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2005, 23, 8664-8670.	1.6	607
20	Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. Journal of Clinical Oncology, 2009, 27, 872-877.	1.6	539
21	Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors. Journal of Clinical Oncology, 2002, 20, 1043-1048.	1.6	511
22	Laparoscopically Assisted vs Open Colectomy for Colon Cancer. Archives of Surgery, 2007, 142, 298.	2.2	485
23	Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841. Journal of Clinical Oncology, 2012, 30, 263-267.	1.6	483
24	Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data. Journal of Clinical Oncology, 2010, 28, 264-271.	1.6	481
25	Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. Journal of Clinical Oncology, 2005, 23, 9243-9249.	1.6	475
26	Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials. Journal of Clinical Oncology, 2005, 23, 2020-2027.	1.6	473
27	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. Journal of the National Cancer Institute, 2011, 103, 863-875.	6.3	469
28	A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery, 2005, 138, 618-630.	1.9	462
29	Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 4085-4091.	1.6	443
30	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	10.7	442
31	Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer. Journal of Clinical Oncology, 2004, 22, 1785-1796.	1.6	419
32	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1383.	7.4	412
33	Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges. Journal of Clinical Oncology, 2009, 27, 4027-4034.	1.6	364
34	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology, 2014, 32, 1277-1280.	1.6	354
35	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 5218-5224.	1.6	321
36	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncology, The, 2015, 16, 937-948.	10.7	286

#	Article	IF	CITATIONS
37	Biomarkers and surrogate end points—the challenge of statistical validation. Nature Reviews Clinical Oncology, 2010, 7, 309-317.	27.6	283
38	Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer. Annals of Surgery, 2019, 269, 589-595.	4.2	283
39	American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. Ca-A Cancer Journal for Clinicians, 2016, 66, 370-374.	329.8	280
40	Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741. Journal of Clinical Oncology, 2008, 26, 5721-5727.	1.6	274
41	Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma. Gastroenterology, 2009, 137, 1270-1279.	1.3	273
42	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. Gastroenterology, 2015, 148, 88-99.	1.3	273
43	Comparison of artificial neural networks with other statistical approaches. Cancer, 2001, 91, 1636-1642.	4.1	256
44	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1453-1486.	1.6	255
45	Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials. Biometrics, 2011, 67, 1047-1056.	1.4	250
46	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. Journal of Clinical Oncology, 2013, 31, 3664-3672.	1.6	233
47	Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line. Journal of Clinical Oncology, 2005, 23, 9441-9442.	1.6	226
48	End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. Journal of Clinical Oncology, 2007, 25, 4569-4574.	1.6	220
49	Drug rechallenge and treatment beyond progression—implications for drug resistance. Nature Reviews Clinical Oncology, 2013, 10, 571-587.	27.6	219
50	Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer. Clinical Cancer Research, 2008, 14, 3408-3415.	7.0	218
51	Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. Clinical Cancer Research, 2012, 18, 1506-1512.	7.0	217
52	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	1.6	216
53	Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 2600-2606.	1.6	211
54	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. Journal of Clinical Oncology, 2006, 24, 3347-3353.	1.6	205

#	Article	IF	CITATIONS
55	Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis Outcomes. Journal of Clinical Oncology, 2010, 28, 256-263.	1.6	204
56	Prognostic Value of <i>BRAFÂ</i> andÂ <i>KRAS</i> ÂMutations in MSI and MSS Stage III Colon Cancer. Journal of the National Cancer Institute, 2017, 109, djw272.	6.3	201
57	Impact of Surgical and Pathologic Variables in Rectal Cancer: A United States Community and Cooperative Group Report. Journal of Clinical Oncology, 2001, 19, 3895-3902.	1.6	199
58	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology, 2010, 28, 3227-3233.	1.6	198
59	Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. Gastroenterology, 2006, 131, 729-737.	1.3	195
60	Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set. Journal of Clinical Oncology, 2008, 26, 2336-2341.	1.6	193
61	Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 1491-1498.	1.6	192
62	Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors. Clinical Cancer Research, 2010, 16, 1884-1893.	7.0	191
63	Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2011, 29, 4620-4626.	1.6	178
64	Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. International Journal of Radiation Oncology Biology Physics, 2002, 52, 469-475.	0.8	171
65	Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology, 2008, 26, 183-189.	1.6	169
66	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	1.6	160
67	An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine, 2006, 25, 2365-2383.	1.6	159
68	Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer. Journal of Clinical Oncology, 2002, 20, 1735-1743.	1.6	158
69	Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. International Journal of Radiation Oncology Biology Physics, 2002, 54, 386-396.	0.8	148
70	The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research, 2010, 16, 1764-1769.	7.0	143
71	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer, 2013, 119, 1528-1536.	4.1	141
72	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	6.3	140

#	Article	IF	CITATIONS
73	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. European Journal of Cancer, 2013, 49, 1565-1577.	2.8	136

DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5

75	The radial distance of extraprostatic extension of prostate carcinoma. , 1999, 85, 2630-2637.		134
76	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1600-1607.	6.3	133
77	Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. Bayesian Analysis, 2012, 7, 639-674.	3.0	132
78	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i> –Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clinical Cancer Research, 2014, 20, 3033-3043.	7.0	129
79	Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. Journal of Clinical Oncology, 2016, 34, 843-853.	1.6	128
80	Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics, 2011, 11, 171-182.	3.1	124
81	Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer. Journal of Clinical Oncology, 2004, 22, 1572-1582.	1.6	119
82	Optimising the design of phase II oncology trials: The importance of randomisation. European Journal of Cancer, 2009, 45, 275-280.	2.8	119
83	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. Journal of Clinical Oncology, 2014, 32, 2975-2982.	1.6	118
84	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. Journal of Clinical Oncology, 2016, 34, 144-150.	1.6	116
85	Decrease in cranial nerve complications after radiosurgery for acoustic neuromas: a prospective study of dose and volume. International Journal of Radiation Oncology Biology Physics, 1999, 43, 305-311.	0.8	112
86	Counting degrees of freedom in hierarchical and other richly-parameterised models. Biometrika, 2001, 88, 367-379.	2.4	110
87	Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130. Journal of Clinical Oncology, 2004, 22, 3277-3283.	1.6	109
88	Molecular Biomarkers for the Evaluation of Colorectal Cancer. Journal of Molecular Diagnostics, 2017, 19, 187-225.	2.8	108
89	Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All. Journal of Biopharmaceutical Statistics, 2009, 19, 530-542.	0.8	106
90	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. JAMA Oncology, 2018, 4, 379.	7.1	104

#	Article	IF	CITATIONS
91	Racial Differences in <i>BRAF</i> / <i>KRAS</i> Mutation Rates and Survival in Stage III Colon Cancer Patients. Journal of the National Cancer Institute, 2015, 107, djv186.	6.3	98
92	Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials. Journal of Clinical Oncology, 2010, 28, 1936-1941.	1.6	96
93	A General Framework for Random Effects Survival Analysis in the Cox Proportional Hazards Setting. Biometrics, 1998, 54, 1486.	1.4	95
94	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6Âmonths) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports, 2013, 9, 261-269.	0.5	94
95	Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial. Journal of Clinical Oncology, 2009, 27, 3671-3676.	1.6	91
96	Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 211-227.	6.3	90
97	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. Journal of the National Cancer Institute, 2018, 110, 638-648.	6.3	90
98	Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Annals of Surgical Oncology, 2006, 13, 887-898.	1.5	89
99	Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials, 2010, 7, 312-321.	1.6	87
100	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	1.6	87
101	Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology, 2017, 35, 552-560.	1.6	87
102	Adaptive adjustment of the randomization ratio using historical control data. Clinical Trials, 2013, 10, 430-440.	1.6	86
103	Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741. Journal of Clinical Oncology, 2011, 29, 1599-1606.	1.6	85
104	Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas. PLoS ONE, 2012, 7, e42274.	2.5	84
105	Predictive biomarker validation in practice: lessons from real trials. Clinical Trials, 2010, 7, 567-573.	1.6	83
106	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. JAMA Oncology, 2017, 3, 472.	7.1	82
107	A flexible design for multiple armed screening trials. Statistics in Medicine, 2001, 20, 1051-1060.	1.6	81
108	Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials, 2007, 8, 14.	1.6	81

#	Article	IF	CITATIONS
109	Clinical implications of microsatellite instability in sporadic colon cancers. Current Opinion in Oncology, 2009, 21, 369-373.	2.4	80
110	Alternate Endpoints for Screening Phase II Studies. Clinical Cancer Research, 2009, 15, 1873-1882.	7.0	78
111	Randomized Phase II Trials: Inevitable or Inadvisable?. Journal of Clinical Oncology, 2010, 28, 2641-2647.	1.6	78
112	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1667-1670.	6.3	78
113	Adjuvant Therapy in the Elderly: Making the Right Decision. Journal of Clinical Oncology, 2007, 25, 1870-1875.	1.6	75
114	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Archives of Pathology and Laboratory Medicine, 2017, 141, 625-657.	2.5	75
115	A Three-Outcome Design for Phase II Clinical Trials. Contemporary Clinical Trials, 2001, 22, 117-125.	1.9	74
116	Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas. Clinical Cancer Research, 2008, 14, 5810-5818.	7.0	74
117	Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial. Journal of Clinical Oncology, 2009, 27, 4109-4115.	1.6	74
118	An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statistics in Medicine, 2007, 26, 2317-2330.	1.6	72
119	Microsatellite Instability Accounts for Tumor Site-Related Differences in Clinicopathologic Variables and Prognosis in Human Colon Cancers. American Journal of Gastroenterology, 2006, 101, 2818-2825.	0.4	70
120	Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?. Journal of Clinical Oncology, 2008, 26, 1922-1923.	1.6	70
121	Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. International Journal of Clinical Oncology, 2009, 14, 102-111.	2.2	70
122	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical Cancer Research, 2015, 21, 5294-5304.	7.0	70
123	Refining Multimodal Therapy for Rectal Cancer. New England Journal of Medicine, 2001, 345, 690-692.	27.0	68
124	Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741. Journal of Clinical Oncology, 2007, 25, 3469-3474.	1.6	68
125	Long-Term Follow-Up and Individual Item Analysis of Quality of Life Assessments Related to Laparoscopic-Assisted Colectomy in the COST Trial 93-46-53 (INT 0146). Annals of Surgical Oncology, 2011, 18, 2422-2431.	1.5	68
126	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncology, The, 2017, 18, 143-154.	10.7	68

#	Article	IF	CITATIONS
127	Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147. Oncology, 2009, 77, 120-123.	1.9	67
128	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. Journal of Clinical Oncology, 2010, 28, 460-465.	1.6	67
129	Mortality associated with daily bolus 5â€fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer, 2004, 101, 2170-2176.	4.1	66
130	End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Diseaseâ€Free Survival as a Surrogate End Point for Overall Survival?. Oncologist, 2006, 11, 624-629.	3.7	66
131	End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal. Journal of Clinical Oncology, 2007, 25, 3572-3575.	1.6	66
132	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 3656-3663.	1.6	65
133	PHASE II STUDY OF PACLITAXEL AND CISPLATIN FOR ADVANCED UROTHELIAL CANCER. Journal of Urology, 2000, 164, 1538-1542.	0.4	64
134	Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144. Clinical Colorectal Cancer, 2009, 8, 88-93.	2.3	64
135	Surgeon Volume Does Not Predict Outcomes in the Setting of Technical Credentialing. Annals of Surgery, 2008, 248, 746-750.	4.2	63
136	Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. International Journal of Radiation Oncology Biology Physics, 1998, 41, 593-598.	0.8	62
137	ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	62
138	General and statistical hierarchy of appropriate biologic endpoints. Oncology, 2006, 20, 5-9.	0.5	62
139	Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials. Journal of Clinical Oncology, 2011, 29, 2781-2786.	1.6	61
140	Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. Journal of the National Cancer Institute, 2011, 103, 1498-1506.	6.3	61
141	Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups. Clinical Cancer Research, 2012, 18, 256-262.	7.0	61
142	Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews, 2016, 43, 74-82.	7.7	61
143	Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841. Journal of Clinical Oncology, 2009, 27, 2848-2854.	1.6	59
144	Issues in clinical trial design for tumor marker studies. Seminars in Oncology, 2002, 29, 222-230.	2.2	58

ARTICLE IF CITATIONS Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the 145 NCI Investigational Drug Steering Committee. Clinical Cancer Research, 2014, 20, 4210-4217. Title is missing!., 2017, , . 146 56 Modelâ€based phase I designs incorporating toxicity and efficacy for single and dual agent drug 1.6 combinations: Methods and challenges. Statistics in Medicine, 2010, 29, 1077-1083. Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial 148 7.0 54 Aggregation. Clinical Cancer Research, 2005, 11, 6466-6471. Cost implications of new treatments for advanced colorectal cancer. Cancer, 2009, 115, 2081-2091. 149 4.1 54 Randomized Phase II Trials: Time for a New Era in Clinical Trial Design. Journal of Thoracic Oncology, 150 53 1.1 2010, 5, 932-934. Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. Clinical Cancer Research, 2008, 14, 8263-8269. Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategyâ€"An Aide et 152 1.6 51 Recherche en Cancérologie Digestive Group Study. Journal of Clinical Oncology, 2011, 29, 4199-4204. Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. Journal of 1.6 Clinical Oncology, 2012, 30, 406-412. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, The, 154 10.7 49 2012, 13, e196-e204. Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial N0147. Journal of Clinical Oncology, 2013, 31, 49 1.6 2016-2023. Optimism bias leads to inconclusive resultsâ€"an empirical study. Journal of Clinical Epidemiology, 2011, 156 5.0 45 64, 583-593. Clinical Trial Designs for Prospective Validation of Biomarkers. Molecular Diagnosis and Therapy, 3.3 44 2005, 5, 317-325. Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group 158 3.3 43 (NCCTG) trials. International Journal of Oncology, 2010, 36, 601-6. Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 2738-2744. Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation. Journal of 160 1.6 42 Clinical Oncology, 2010, 28, 3002-3007. Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers. Clinical Cancer Research, 2008, 14, 4128-4133. Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; 162 2.3 41 NCCTG (Alliance) Intergroup Trial N0147. Clinical Colorectal Cancer, 2014, 13, 100-109.

#	ARTICLE	IF	CITATIONS
163	Efficacy and Quality-of-Life Data Are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients With Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2002, 20, 4574-4580.	1.6	40
164	Association Study of the let-7 miRNA-Complementary Site Variant in the 3′ Untranslated Region of the <i>KRAS</i> Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). Clinical Cancer Research, 2014, 20, 3319-3327.	7.0	40
165	Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse. Journal of Clinical Oncology, 2014, 32, 841-850.	1.6	40
166	5-Fluorouracil–Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study. Clinical Colorectal Cancer, 2005, 4, 325-331.	2.3	39
167	A flexible approach to time-varying coefficients in the Cox regression setting. Lifetime Data Analysis, 1997, 3, 13-25.	0.9	38
168	Early Detection of Toxicity and Adjustment of Ongoing Clinical Trials: The History and Performance of the North Central Cancer Treatment Group's Real-Time Toxicity Monitoring Program. Journal of Clinical Oncology, 2002, 20, 4591-4596.	1.6	37
169	Dealing With a Deluge of Data: An Assessment of Adverse Event Data on North Central Cancer Treatment Group Trials. Journal of Clinical Oncology, 2005, 23, 9275-9281.	1.6	37
170	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2492-2500.	2.5	37
171	Blinded Independent Central Review of the Progression-Free Survival Endpoint. Oncologist, 2010, 15, 492-495.	3.7	37
172	Genotype-based clinical trials in cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 475-487.	13.7	37
173	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 124-128.	2.3	37
174	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. Journal of Clinical Oncology, 2017, 35, 1929-1937.	1.6	37
175	Statistical Issues in Tumor Marker Studies. Archives of Pathology and Laboratory Medicine, 2000, 124, 1011-1015.	2.5	37
176	Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma. Journal of Immunotherapy, 2000, 23, 430-437.	2.4	36
177	Title is missing!. Annals of Surgery, 2003, 237, 502-508.	4.2	36
178	Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials. Journal of Clinical Oncology, 2009, 27, 5958-5964.	1.6	36
179	New Treatment Options for Colorectal Cancer. New England Journal of Medicine, 2004, 351, 391-392.	27.0	35
180	Systematic review of statistical methods used in molecular marker studies in cancer. Cancer, 2008, 112, 1862-1868.	4.1	35

#	Article	IF	CITATIONS
181	Evaluation of the Optimal Number of Lesions Needed for Tumor Evaluation Using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group Investigation. Journal of Clinical Oncology, 2009, 27, 3205-3210.	1.6	34
182	Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set. Journal of Clinical Oncology, 2012, 30, 2334-2339.	1.6	34
183	Exploring racial differences in outcome and treatment for metastatic colorectal cancer. Cancer, 2012, 118, 1083-1090.	4.1	34
184	The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community. European Journal of Cancer, 2014, 50, 260-266.	2.8	34
185	The radial distance of extraprostatic extension of prostate carcinoma. Cancer, 1999, 85, 2630-2637.	4.1	34
186	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer, 2005, 104, 1871-1884.	4.1	33
187	Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet, The, 2007, 370, 105-107.	13.7	33
188	Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. Journal of Clinical Oncology, 2011, 29, 4719-4720.	1.6	33
189	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	3.7	33
190	Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. International Journal of Cancer, 2007, 120, 1232-1238.	5.1	32
191	Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. Journal of Clinical Oncology, 2016, 34, 1182-1189.	1.6	32
192	Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology, 2017, 147, 221-260.	0.7	32
193	A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3NO-N3MO squamous cell carcinoma of the upper aerodigestive tract. Cancer, 2005, 103, 559-568.	4.1	31
194	Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. Journal of Clinical Pathology, 2010, 63, 530-537.	2.0	31
195	What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?. Oncologist, 2010, 15, 19-23.	3.7	31
196	Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. Biostatistics, 2011, 12, 478-492.	1.5	31
197	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 1036-1043.	7.0	31
198	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1305-1310.	0.8	30

#	Article	IF	CITATIONS
199	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Annals of Surgical Oncology, 2011, 18, 3261-3270.	1.5	30
200	ROBUST BAYESIAN APPROACHES FOR CLINICAL TRIAL MONITORING. , 1996, 15, 1093-1106.		29
201	Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX). Cancer, 2007, 110, 670-677.	4.1	29
202	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Journal of Oncology Practice, 2017, 13, 333-337.	2.5	29
203	Intraoperative radiotherapy for head and neck and skull base cancer. Head and Neck, 2003, 25, 217-226.	2.0	28
204	Randomized Clinical Trial of High-Dose Levamisole Combined with 5-Fluorouracil and Leucovorin as Surgical Adjuvant Therapy for High-Risk Colon Cancer. Clinical Colorectal Cancer, 2006, 6, 133-139.	2.3	28
205	The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment. Journal of the National Cancer Institute, 2015, 107, djv157.	6.3	28
206	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients. Pharmacogenetics and Genomics, 2016, 26, 133-137.	1.5	28
207	Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?. Journal of Clinical Oncology, 2004, 22, 2978-2981.	1.6	27
208	FDG-PET Lymphoma Demonstration Project Invitational Workshop. Academic Radiology, 2007, 14, 330-339.	2.5	27
209	Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials. Clinical Cancer Research, 2011, 17, 6592-6599.	7.0	27
210	A review of phase II trial designs for initial marker validation. Contemporary Clinical Trials, 2013, 36, 597-604.	1.8	27
211	The Predictive and Prognostic Value of Sex inÂEarly-Stage Colon Cancer: A Pooled Analysis ofÂ33,345 Patients from the ACCENT Database. Clinical Colorectal Cancer, 2013, 12, 179-187.	2.3	27
212	Surrogate endpoint validation: statistical elegance versus clinical relevance. Statistical Methods in Medical Research, 2008, 17, 477-486.	1.5	26
213	Bayesian adjusted <i>R</i> ² for the metaâ€analytic evaluation of surrogate timeâ€toâ€event endpoints in clinical trials. Statistics in Medicine, 2012, 31, 743-761.	1.6	26
214	Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. Clinical Trials, 2013, 10, 647-652.	1.6	26
215	Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. International Journal of Radiation Oncology Biology Physics, 2002, 54, 409-413.	0.8	25
216	Smoothing Balanced Single-Error-Term Analysis of Variance. Technometrics, 2007, 49, 12-25.	1.9	25

#	Article	IF	CITATIONS
217	Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Journal of Clinical Oncology, 2007, 25, 2313-2321.	1.6	25
218	Prognostic webâ€based models for stage II and III colon cancer. Cancer, 2011, 117, 4155-4165.	4.1	25
219	Surgical Quality Surrogates Do Not Predict Colon Cancer Survival in the Setting of Technical Credentialing. Annals of Surgery, 2013, 257, 102-107.	4.2	25
220	Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology. JAMA Oncology, 2017, 3, e170123.	7.1	25
221	FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer. Journal of Clinical Oncology, 2005, 23, 3311-3313.	1.6	23
222	Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials Program. Journal of Clinical Oncology, 2010, 28, 527-530.	1.6	23
223	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. Computational Statistics and Data Analysis, 2011, 55, 2748-2757.	1.2	23
224	Adjuvant Therapy for Colon Cancer — The Pace Quickens. New England Journal of Medicine, 2005, 352, 2746-2748.	27.0	22
225	All-Comers versus Enrichment Design Strategy in Phase II Trials. Journal of Thoracic Oncology, 2011, 6, 658-660.	1.1	21
226	Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments. Current Oncology Reports, 2011, 13, 42-49.	4.0	21
227	Design of clinical trials for biomarker research in oncology. Clinical Investigation, 2011, 1, 1627-1636.	0.0	21
228	Modelâ€based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer, 2010, 116, 1691-1698.	4.1	20
229	Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials, 2011, 8, 591-600.	1.6	20
230	Current Issues in Oncology Drug Development, with a Focus on Phase II Trials. Journal of Biopharmaceutical Statistics, 2009, 19, 556-562.	0.8	19
231	Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit. Clinical Trials, 2012, 9, 283-292.	1.6	19
232	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1402-1410.	2.5	18
233	Prediction of Radial Distance of Extraprostatic Extension FromÂPretherapy Factors. International Journal of Radiation Oncology Biology Physics, 2007, 69, 411-418.	0.8	18
234	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. Clinical Cancer Research, 2014, 20, 4361-4369.	7.0	18

#	Article	IF	CITATIONS
235	Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute, 2015, 107, djv239.	6.3	18
236	Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research. Journal of the National Cancer Institute, 2016, 108, djw154.	6.3	18
237	A 2-Stage Phase II Design with Direct Assignment Option in Stage II for Initial Marker Validation. Clinical Cancer Research, 2012, 18, 4225-4233.	7.0	17
238	Genomic advances and their impact on clinical trial design. Genome Medicine, 2009, 1, 69.	8.2	16
239	Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741. Oncologist, 2011, 16, 859-867.	3.7	16
240	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. International Journal of Cancer, 2016, 139, 986-995.	5.1	16
241	Flexible Bayesian Survival Modeling with Semiparametric Time-Dependent and Shape-Restricted Covariate Effects. Bayesian Analysis, 2016, 11, 381-402.	3.0	16
242	A north central cancer treatment group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer, 2000, 89, 1699-1705.	4.1	15
243	Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology, 2012, 47, 356-362.	1.5	15
244	Metaâ€analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling. Biometrics, 2012, 68, 226-232.	1.4	15
245	Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II Trials. Journal of Clinical Oncology, 2015, 33, 36-41.	1.6	15
246	Is En-Bloc Resection of Locally Recurrent Rectal Carcinoma Involving the Urinary Tract Indicated?. Annals of Surgical Oncology, 2006, 13, 740-744.	1.5	14
247	Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis. Cancer Investigation, 2008, 26, 439-444.	1.3	14
248	Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer. Biometrics, 2009, 65, 1030-1040.	1.4	14
249	Designing a Randomized Clinical Trial to Evaluate Personalized Medicine: A New Approach Based on Risk Prediction. Journal of the National Cancer Institute, 2010, 102, 1756-1759.	6.3	14
250	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. Biometrics, 2012, 68, 248-257.	1.4	14
251	On Bayesian methods of exploring qualitative interactions for targeted treatment. Statistics in Medicine, 2012, 31, 3693-3707.	1.6	14
252	A Bayesian doseâ€finding design incorporating toxicity data from multiple treatment cycles. Statistics in Medicine, 2017, 36, 67-80.	1.6	14

#	Article	IF	CITATIONS
253	Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls. Journal of Clinical Oncology, 2003, 21, 395-396.	1.6	13
254	Current Use and Surgical Efficacy of Laparoscopic Colectomy in Colon Cancer. Journal of the American College of Surgeons, 2013, 217, 56-62.	0.5	13
255	Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTALÂand COIN-B trials in the ARCAD database. European Journal of Cancer, 2018, 103, 205-213.	2.8	13
256	Disease-Free Survival in Colon Cancer: Still Relevant After All These Years!. Journal of Clinical Oncology, 2013, 31, 1609-1610.	1.6	12
257	NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. Oncologist, 2009, 14, 970-978.	3.7	11
258	Clinical Trials Data Collection: When Less Is More. Journal of Clinical Oncology, 2010, 28, 5019-5021.	1.6	11
259	Randomized Phase II Clinical Trials. Journal of Biopharmaceutical Statistics, 2014, 24, 802-816.	0.8	11
260	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 696-703.	2.5	11
261	Statistical Considerations for the Next Generation of Clinical Trials. Seminars in Oncology, 2011, 38, 598-604.	2.2	10
262	Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1199.	7.4	10
263	Center-within-trial versus trial-level evaluation of surrogate endpoints. Computational Statistics and Data Analysis, 2014, 78, 1-20.	1.2	10
264	Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). Journal of Geriatric Oncology, 2018, 9, 24-31.	1.0	10
265	An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. Journal of Biopharmaceutical Statistics, 2019, 29, 271-286.	0.8	10
266	Sample Size and Design Considerations for Phase II Clinical Trials with Correlated Observations. Contemporary Clinical Trials, 1999, 20, 242-252.	1.9	9
267	A new graphic for quality adjusted life years (Q-TWiST) survival analysis: the Q-TWiST plot. Quality of Life Research, 2002, 11, 37-45.	3.1	9
268	Sam Wieand, PhD. Journal of Clinical Oncology, 2006, 24, 4523-4525.	1.6	9
269	Causal Effects of Treatments for Informative Missing Data due to Progression/Death. Journal of the American Statistical Association, 2010, 105, 912-929.	3.1	9
270	The ARCAD Clinical Trials Program: An Update and Invitation. Oncologist, 2012, 17, 188-191.	3.7	9

#	Article	IF	CITATIONS
271	Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. Journal of Biopharmaceutical Statistics, 2015, 25, 857-877.	0.8	9
272	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. Journal of Geriatric Oncology, 2016, 7, 422-429.	1.0	9
273	One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancer. Journal of the National Cancer Institute, 2016, 108, djw011.	6.3	9
274	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist, 2017, 22, 189-198.	3.7	9
275	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance) Journal of Clinical Oncology, 2017, 35, 3579-3579.	1.6	9
276	Comparing and Validating Simple Measures of Patient- Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiology & Pain Management, 2015, 2, .	0.1	9
277	Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology, 2014, 3, 14.	1.2	9
278	Pick the Winner Designs in Phase II Cancer Clinical Trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	1.1	8
279	Early Stopping for Benefit in National Cancer Institute–Sponsored Randomized Phase III Trials: The System Is Working. Journal of Clinical Oncology, 2009, 27, 1543-1544.	1.6	8
280	Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint. Biometrics, 2012, 68, 258-267.	1.4	8
281	Shifting paradigms in cancer clinical trial design. Nature Reviews Clinical Oncology, 2014, 11, 625-626.	27.6	8
282	Adjuvant Therapy for Colon Cancer. JAMA Oncology, 2016, 2, 1133.	7.1	8
283	New insights into the evaluation of randomized controlled trials for rare diseases over a longâ€ŧerm research horizon: a simulation study. Statistics in Medicine, 2016, 35, 3245-3258.	1.6	8
284	Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. Clinical Trials, 2011, 8, 581-590.	1.6	7
285	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. Oncologist, 2017, 22, 1415-1418.	3.7	7
286	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials, 2017, 14, 611-620.	1.6	7
287	Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). Journal of Gastrointestinal Oncology, 2017, 8, 1-11.	1.4	7
288	Mining the ACCENT database: a review and update. Chinese Clinical Oncology, 2013, 2, 18.	1.2	7

#	Article	IF	CITATIONS
289	North Central Cancer Treatment Group—Achievements and Perspectives. Seminars in Oncology, 2008, 35, 530-544.	2.2	6
290	Calibration of Quality-Adjusted Life Years forÂOncology Clinical Trials. Journal of Pain and Symptom Management, 2014, 47, 1091-1099.e3.	1.2	6
291	Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. Journal of Clinical Oncology, 2015, 33, 4048-4057.	1.6	6
292	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer, 2015, 90, 281-287.	2.0	6
293	Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. Journal of Clinical Oncology, 2016, 34, 3711-3712.	1.6	6
294	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. Chinese Clinical Oncology, 2016, 5, 80-80.	1.2	6
295	CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATH. Journal of the American Statistical Association, 2010, 105, 912-929.	3.1	6
296	New Lessons From "Old―Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 4532-4534.	1.6	5
297	Adjuvant Therapy for Colon Cancer: Learning from the Past to Inform the Future. Annals of Surgical Oncology, 2010, 17, 947-949.	1.5	5
298	Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications, 2020, 17, 100492.	1.1	5
299	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. Blood, 2016, 128, 3027-3027.	1.4	5
300	Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chinese Clinical Oncology, 2014, 3, .	1.2	5
301	Pick the Winner Designs in Phase II Cancer Clinical Trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	1.1	4
302	Failure of bevacizumab in early-stage colon cancer. Nature Reviews Clinical Oncology, 2011, 8, 10-11.	27.6	4
303	Application of Tumor Measurement–Based Metrics in the Real World. Journal of Clinical Oncology, 2013, 31, 4374-4374.	1.6	4
304	Improved Outcomes in Metastatic Colon Cancer. JAMA Oncology, 2015, 1, 795.	7.1	4
305	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. Journal of Biopharmaceutical Statistics, 2018, 28, 451-462.	0.8	4
306	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. JCO Precision Oncology, 2020, 4, 116-127.	3.0	4

#	Article	IF	CITATIONS
307	Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. PLoS ONE, 2014, 9, e94727.	2.5	4
308	Adverse-event rates: journals versus databases. Lancet, The, 2007, 369, 171-172.	13.7	3
309	A falseâ€discoveryâ€rateâ€based loss framework for selection of interactions. Statistics in Medicine, 2008, 27, 2004-2021.	1.6	3
310	Reply to D.J. Stewart. Journal of Clinical Oncology, 2010, 28, e652-e653.	1.6	3
311	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage Il Colon Cancer: A Systematic Pooled Data Analysis. Clinical Colorectal Cancer, 2015, 14, 99-105.	2.3	3
312	Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. Journal of Clinical Oncology, 2016, 34, 3949-3950.	1.6	3
313	Outcomes for Elderly Patients (pts) with Follicular Lymphoma (FL) Using Individual Patient Data (IPD) from 5922 Pts in 18 Randomized Controlled Trials (RCTs): a Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) Group Study. Blood, 2016, 128, 1102-1102.	1.4	3
314	Pick the winner designs in phase II cancer clinical trials. Journal of Thoracic Oncology, 2006, 1, 5-6.	1.1	3
315	Sound Footing or Slippery Slope? The Value of Secondary Analyses of Randomized Trials. Journal of Clinical Oncology, 2007, 25, 3191-3193.	1.6	2
316	CAIRO and FOCUS – Authors' reply. Lancet, The, 2007, 370, 1905.	13.7	2
317	Systemic Therapy for Elderly Patients with Gastrointestinal Cancer. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6983.	1.3	2
318	Rejoinder for "Metaâ€analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling― Biometrics, 2012, 68, 245-247.	1.4	2
319	A phase II flexible screening design allowing for interim analysis and comparison with historical control. Contemporary Clinical Trials, 2013, 35, 128-137.	1.8	2
320	Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemporary Clinical Trials, 2014, 38, 157-162.	1.8	2
321	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration. Forum of Clinical Oncology, 2014, 5, 1-7.	0.2	2
322	The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-6.	1.3	2
323	New Adjuvant Trial Designs in Colon Cancer. Current Colorectal Cancer Reports, 2015, 11, 326-334.	0.5	2
324	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer, 2018 96 115-124	2.8	2

#	Article	IF	CITATIONS
325	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance) Journal of Clinical Oncology, 2017, 35, 3516-3516.	1.6	2
326	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association, 2010, 121, 21-32; discussion 32-3.	0.5	2
327	Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clinical Colorectal Cancer, 2009, 8, 88-93.	2.3	2
328	Duffy-Santner Confidence Intervals for the Two-Stage Three-Outcome Design. Journal of Biopharmaceutical Statistics, 2006, 16, 875-880.	0.8	1
329	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. Current Colorectal Cancer Reports, 2008, 4, 155-159.	0.5	1
330	Evolving end points for clinical trials in advanced colorectal cancer. Current Colorectal Cancer Reports, 2009, 5, 135-139.	0.5	1
331	Reply to M. Chao et al. Journal of Clinical Oncology, 2009, 27, e281-e281.	1.6	1
332	Reply to M.A. Rosen et al. Journal of Clinical Oncology, 2010, 28, e161-e161.	1.6	1
333	Reply to S.A. Kesikli et al. Journal of Clinical Oncology, 2012, 30, 2288-2289.	1.6	1
334	From isolated hypotheses to connected practical studies: statisticians' role in a seamless targeted therapy development. Future Medicinal Chemistry, 2012, 4, 943-945.	2.3	1
335	CRM Trials for Assessing Toxicity and Efficacy. , 2012, , 85-96.		1
336	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. Blood, 2016, 128, 4196-4196.	1.4	1
337	A phase II trial design with direct assignment option for initial marker validation Journal of Clinical Oncology, 2012, 30, 34-34.	1.6	1
338	Genomic classifiers in colon cancer - clinical utility. Gastrointestinal Cancer Research: GCR, 2008, 2, S35-7.	0.7	1
339	Reply to F. Montagnani et al. Journal of Clinical Oncology, 2009, 27, e134-e135.	1.6	Ο
340	Reply to C.D. Atkins. Journal of Clinical Oncology, 2010, 28, e747-e747.	1.6	0
341	Reply to P. Prassopoulos et al. Journal of Clinical Oncology, 2010, 28, e82-e82.	1.6	0
342	Reply to I.D. Nagtegaal et al. Journal of Clinical Oncology, 2010, 28, e399-e400.	1.6	0

#	Article	IF	CITATIONS
343	Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities. The Journal of Oncopathology, 2014, 2, 37-45.	0.1	0
344	Statistics and Clinical Trials. , 2016, , 239-252.e1.		0
345	Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the Power of Pooled Individual Patient Data from Multiple Clinical Trials. Current Colorectal Cancer Reports, 2016, 12, 251-259.	0.5	0
346	Testing of evaluation bias for progression free survival endpoint in oncology clinical trials. Statistics in Medicine, 2016, 35, 3923-3932.	1.6	0
347	Clinical Validation of Biomarkers in Cancer. , 2010, , 227-250.		0
348	Phase III Clinical Trials with Anticancer Agents. , 2011, , 163-188.		0
349	Statistics and Clinical Trials. , 2012, , 223-237.		0
350	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147 Journal of Clinical Oncology, 2012, 30, 446-446.	1.6	0
351	Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair Journal of Clinical Oncology, 2012, 30, 460-460.	1.6	0
352	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis Journal of Clinical Oncology, 2012, 30, 443-443.	1.6	0
353	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	1.0	0
354	Importance of randomization in early clinical trials. Clinical Advances in Hematology and Oncology, 2009, 7, 249-51.	0.3	0
355	Gastrointestinal Cancers. , 0, , 81-104.		0
356	Introduction to special issue on biomarker-based clinical trial designs in oncology. Chinese Clinical Oncology, 2015, 4, 28.	1.2	0